TNF-α further contributes to resistance by activating the NF-κB pathway, upregulating inhibitors of apoptosis proteins (IAPs) and other factors [96], and a recent systematic review of studies conducted in breast cancer patients suggests that higher TNF-α levels correlate with reduced chemotherapy efficacy, although more rigorous studies are needed [97]. The gene discussed is NFKB1; the disease is breast carcinoma.